Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2023-12-01 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
전환가액의조정(제27회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (27th series) due to a decline in market price. This type of disclosure relates to changes in the company's capital structure and financial instruments. Since it specifically details the adjustment of conversion prices and the resulting change in the number of convertible shares, it falls under the category of capital and financing updates.
2023-12-01 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from Cellumed regarding the issuance of bonds with warrants (신주인수권부사채 발행결정). It details the terms of the bond issuance, including interest rates, maturity dates, put options, and warrant exercise prices, and specifically includes a 'Correction Report' (정정신고) section detailing changes to the original filing. This falls under the category of capital and financing updates as it relates to the company's debt and equity financing activities.
2023-11-23 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Cellumed' (주식회사 셀루메드) covering the period from January 1, 2023, to September 30, 2023. It contains detailed business descriptions, product information, production capacity, and sales data, which are characteristic of an interim financial report. It is not an announcement of a report (RPA) or a simple certification (RNS), as it provides substantive financial and operational data. 9M 2023
2023-11-13 Korean
[정정제출요구][기재정정]증권신고서(채무증권)
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment filed by Cellumed. It explicitly states it is a 'Correction Report' (정정신고) due to the submission of the 3rd Quarter Report (3분기보고서). It contains detailed financial tables, business risk assessments, and management discussions that have been updated to reflect the latest quarterly data. Since this is a formal regulatory filing for securities registration and not merely an announcement of a report's availability, it falls under the category of Regulatory Filings.
2023-11-13 Korean
[기재정정]증권신고서(채무증권)
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Korean financial regulatory authority (FSS/DART). It details a correction (정정신고) to a previously filed registration statement regarding the issuance of debt securities (specifically, bonds with warrants). It includes detailed amendments to the terms of the bonds, business risks, and financial disclosures. This is a formal regulatory filing required for public offerings of securities.
2023-11-02 Korean
전환가액의조정(제25회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the Korean stock exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB). It details the specific changes to the conversion price, the number of shares, and the underlying reasons (market price decline). This type of disclosure is a standard corporate action related to capital structure and financing, which falls under the 'Capital/Financing Update' category.
2023-11-02 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.